Y
Yasushi Omuro
Researcher at Tokyo Metropolitan Komagome Hospital
Publications - 58
Citations - 7086
Yasushi Omuro is an academic researcher from Tokyo Metropolitan Komagome Hospital. The author has contributed to research in topics: Cancer & Ramucirumab. The author has an hindex of 16, co-authored 51 publications receiving 5899 citations. Previous affiliations of Yasushi Omuro include Anhui Medical University.
Papers
More filters
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study
Taroh Satoh,Rui-Hua Xu,Hyun Cheol Chung,Guo-ping Sun,Toshihiko Doi,Jianming Xu,Akihito Tsuji,Yasushi Omuro,Jin Li,Jinwan Wang,Hiroto Miwa,Shukui Qin,Ik-Joo Chung,Kun-Huei Yeh,Jifeng Feng,Akihira Mukaiyama,Mikiro Kobayashi,Atsushi Ohtsu,Yung-Jue Bang +18 more
TL;DR: Lapatinib plus paclitaxel demonstrated activity in the second-line treatment of patients with HER2 FISH-positive IHC3+ advanced gastric cancer but did not significantly improve OS in the intent-to-treat population.
Journal ArticleDOI
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Hideki Ueno,Masafumi Ikeda,Makoto Ueno,Nobumasa Mizuno,Tatsuya Ioka,Yasushi Omuro,Takako Eguchi Nakajima,Junji Furuse +7 more
TL;DR: Nab-paclitaxel plus gemcitabine regimen showed highly promising efficacy with manageable safety profile under careful observation and with appropriate supportive care in Japanese patients with metastatic pancreatic cancer.
Journal ArticleDOI
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Akira Sawaki,Yasuo Ohashi,Yasushi Omuro,Taroh Satoh,Yasuo Hamamoto,Narikazu Boku,Yoshinori Miyata,Hiroya Takiuchi,Kensei Yamaguchi,Yasutsuna Sasaki,Tomohiro Nishina,Atsushi Satoh,Eishi Baba,Takao Tamura,Takashi Abe,Kiyohiko Hatake,Atsushi Ohtsu +16 more
TL;DR: Overall survival of Japanese patients with human epidermal growth factor 2 positive advanced/metastatic gastric or gastroesophageal junction cancer who received trastuzumab plus chemotherapy was improved compared with patients who received chemotherapy alone.
Journal ArticleDOI
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Kohei Shitara,Kei Muro,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Yoshito Komatsu,Tomohiro Nishina,Kensei Yamaguchi,Yoshihiko Segawa,Yasushi Omuro,Takao Tamura,Toshihiko Doi,Seigo Yukisawa,Hirofumi Yasui,Fumio Nagashima,Masahiro Gotoh,Taito Esaki,Michael Emig,Kumari Chandrawansa,Astra M. Liepa,Hansjochen Wilke,Yukako Ichimiya,Atsushi Ohtsu +22 more
TL;DR: Safety profiles of the ramucirumab plus paclitaxel arm were similar between populations, though there was a higher incidence of neutropenia in Japanese patients, and progression-free survival and objective response rate improvements were observed in both populations.